Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization

Current Eye Research

Volumn 26, Issue 1, 2003, Pages 45-54

  Danis, Ronald P ^a   Criswell, Mark H ^a   Orge, Faruk ^a   Wancewicz, Edward V ^b   Stecker, Kim ^b   Henry, Scott P ^b   Monia, Brett P ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Animal models; Antisense; C raf 1 kinase; Ischemia; Neovascularization; Oligonucleotide

Indexed keywords

ANGIOGENESIS INHIBITOR; CHIMERIC PROTEIN; ISIS 107189; MESSENGER RNA; PHOSPHOROTHIOIC ACID; RAF 1 KINASE ANTISENSE OLIGONUCLEOTIDE; RAF PROTEIN; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE;

3' UNTRANSLATED REGION; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENUCLEATION; ENZYME INHIBITION; FROZEN SECTION; GEL ELECTROPHORESIS; GENE EXPRESSION REGULATION; GENE REPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MULTIPLE DRUG DOSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANK SUM TEST; RETINA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; SWINE; VASCULAR ENDOTHELIUM; ANIMAL; CELL LINE; DRUG ANTAGONISM; EYE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RETINA BLOOD VESSEL; VITREOUS BODY;

ANIMALS; CELL LINE; EYE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-RAF; RETINAL VEIN OCCLUSION; RETINAL VESSELS; SWINE; VITREOUS BODY;

EID: 0042767766     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.26.1.45.14252     Document Type: Article

References (29)

1. Yoshida A, Yoshida S, Ishibashi T, Inomata H. Intraocular neovascularization. Histol Histopathol. 1999;14:1287-1294.
2. Aiello LP. Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354-362.
3. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci. 1994;19:474-480.
4. Clark EA, Brugge JS. Integrins and signal transduction pathways: The road taken. Science. 1995;268:233-239.
5. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18:2221-2230.
6. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem. 1997;67:353-366.
7. Monia BP, Johnstone JE, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 1996;2:668-675.
8. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM. Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993;268:14514-14522.
9. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, Bennett CF. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem. 1997;272:11994-12000.
10. Bennett CF, Chiang M-Y, Chan H, Shoemaker JEE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmcol. 1992;41:1023-1033.
11. Condon TP, Gonzales JEN, Ill CR. Different electric field strengths for maximum efficiency or expression in electroploation. Focus. 1991;13:33-35.
12. Danis RP, Yang Y, Massicotte SJ, Boldt C. Preretinal and optic nerve head neovascularization induced by photodynamic venous thrombosis in domestic pigs. Arch Ophthalmol. 1993;111:539-543.
13. Geary RS, Matson J, Levin AA. A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal Biochem. 1999;274:241-248.
14. Leeds JM, Graham MJ, Troung L, Cummins LL. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem. 1996;235:36-43.
15. Leeds JM, Henry SP, Truong L, Zutsi A, Levin AA, Kornbrust DJ. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injections in the rabbit. Drug Metab Dispos. 1997;25:921-926.
16. Xu XS, Vanderziel C, Bennett CF, Monia BP. A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules. J Biol Chem. 1998;273:33230-33238.
17. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmund J, Dorr FA, Yao K-S. c-raf-1 depletion and tumor responses in patients treated with the c-raf-l antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res. 1999;5:3977-3982.
18. Monteith DK, Geary RS, Johnston J, Monia BP, Levin AA. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol Sci. 1998;46:365-375.
19. Cioffi CL, Garay M, Johnston JF, McGraw K, Boggs RT, Hreniuk D, Monia BP. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of A-Raf and C-Raf in serum-induced proliferation. Mol Pharmcol. 1997;51:383-389.
20. Mandiyan S, Schumacher C, Cioffi C, Sharif H, Yuryev A, Lappe R, Monia B, Hanson S, Goff S, Wennogle L. Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997;7:539-548.
21. Rakoczy PE, Lai MC, Watson M, Seydel U, Constable I. Targeted delivery of an antisense oligonucleotide in the retina: Uptake, distribution, stability, and effect. Antisense Nucleic Acid Drug Dev. 1996;6:207-213.
22. Leeds JM, Henry SP, Bistner S, Scherrill S, Williams K, Levin AA. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab Dispos. 1998;26:670-675.
23. Pari GS, Field AK, Smith JA. Potent antiviral activity of an antisense oligonucleotide complementary to the intronexon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob Agents Chemother. 1995;39:1157-1161.
24. Azad RP, Driver VB, Tanaka K, Crooke RM, Graham M. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother. 1993;37:1945-1954.
25. Perry CM, Barman Balfour JA. Fomivirsen. Drugs. 1999; 57:375-380.
26. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LEH. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
27. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:697-707.
28. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, Campochiaro PA. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol. 1999;154:1743-1753.
29. Aiello LP, Bursell S-E, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LEH, King GL. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.